---
title: "letter uowel oustruction tirzepatide"
year: 2024
month: 12
journal: "American Family Physician"
volume: "109-110"
issue: "12"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-12-letter-bowel-obstruction-tirzepatide.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# letter uowel oustruction tirzepatide

Letters to the Editor

Case Report: Small Bowel Obstruction After                               Author disclosure: No relevant financial relationships.

Starting Tirzepatide (Mounjaro)
                                                                         REFERENCES
                                                                          1. Watanabe JH, Kwon J, Nan B, et al. Trends in glucagon-like peptide
To the Editor: A 66-year-old woman with history of recur-                    1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003).
rent ventral incisional hernia, multiple abdominal surgeries,                2024;64(1):133-138.
small bowel obstruction, type 2 diabetes, and class III obe-              2. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1
sity presented to the emergency department with 2 days of                    Investigators. Tirzepatide once weekly for the treatment of obesity.
                                                                             N Engl J Med. 2022;387(3):205-216.
abdominal pain, nausea, vomiting, and belching. She had
                                                                          3. Sodhi M, Rezaeianzadeh R, Kezouh A, et al. Risk of gastrointestinal
been taking tirzepatide (Mounjaro), 2.5 mg/week, for 2                       adverse events associated with glucagon-like peptide-1 receptor
weeks, and had lost 3.18 kg (7 lb). Radiography showed dis-                  agonists for weight loss. JAMA. 2023;330(18):1795-1797.
tended loops of the small bowel, and laboratory tests showed              4. U.S. Food and Drug Administration. Ozempic (Semaglutide).
mild dehydration. Abdominal computed tomography found                        Safety-related labeling changes approved by FDA Center for Drug
                                                                             Evaluation and Research (CDER). September 22, 2023. Accessed
a small bowel obstruction with the transition point at the
                                                                             November 7, 2024. https://www.accessdata.fda.gov/scripts/
entrance of the ventral hernia. After nasogastric tube place-                cder/safetylabelingchanges/index.cfm?event=searchdetail.
ment and fluids, she passed bowel movements, and small                       page&DrugNameID=2183
bowel follow-through showed partial small bowel obstruc-                  5. Rao K, Nimako EK. SAT680 Mounjaro: a side effect. J Endocr Soc.
tion. She was discharged with instructions to discontinue                    2023;7(suppl 1):bvad114.128.

tirzepatide.                                                              6. Mathew A, Hannoodee H. FRI643 tirzepatide associated partial
                                                                             small bowel obstruction: a case report. J Endocr Soc. 2023;7(suppl
   The use of tirzepatide, a glucagon-like peptide-1 and glucose-
                                                                             1):bvad114.862.
dependent insulinotropic polypeptide receptor agonist, showed
a monthly prescribing growth rate of 254% over 7 months
in 2022, likely due to the benefit of weight loss.1,2 Despite
increased prescription frequency, a 2023 cohort study showed             Correction
serious adverse gastrointestinal events (eg, bowel obstruction)          Incorrect CME Quiz Answers. In the “Answers to This Issue’s
in individuals taking medications similar to tirzepatide.3 In            CME Quiz” box (October 2024, p. 443), the answers listed for
September 2023, the US Food and Drug Administration added                the first four questions were incorrect. The corrected answer
a boxed warning for ileus to the approved drug label for sema-           box for the October 2024 CME quiz is reprinted below. The
glutide (Ozempic).4                                                      online CME quiz was not affected by this error. ■
   This case and two 2023 case reports identify bowel obstruc-
tions in individuals taking tirzepatide, offering compelling rea-
sons for it to carry a warning of this potential adverse effect.5,6
Family physicians managing type 2 diabetes and obesity should                  Answers to This Issue’s CME Quiz
identify components of a patient’s history that could increase
the risk for bowel obstruction before prescribing a glucagon-               Q1. A             Q5. B             Q9. D            Q13. D
like peptide-1 agonist.                                                     Q2. D             Q6. C             Q10. B           Q14. C
                                                                            Q3. A             Q7. B             Q11. B           Q15. D
Leandra Morgenthaler, BA                                                    Q4. D             Q8. C             Q12. B           Q16. B
Columbia, Mo.

Regina DePietro, MD, DABOM
Columbia, Mo.                                                              Email submissions to afplet@aafp.org.
rhdwb9@health.missouri.edu




              Downloaded from the American Family Physician website at www.aafp.org/afp. Copyright © 2024 American Acad-
562 American Family Physician	                                                                          Volume 110, Number 6 • December 2024
               emy of Family Physicians. For the private, noncommercial use of one individual user of the website. All other rights
                           reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
